id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-336026-x02f7byo	Lommatzsch, Marek	COVID‐19 in a patient with severe asthma treated with Omalizumab	2020-06-27		.txt	text/plain	650	52	56	1, 3, 4 This is supwith asthma following Omalizumab treatment is primarily mediated by a downregulation of the high-affinity IgE receptor on pDCs. 8, 9 Thus, we hypothesize that the patient described in this case report might have been protected from an asthma exacerbation or pneumonia during COVID-19, either because of the underlying disease (allergic asthma) or because of the antibody used for treatment (Omalizumab), or both. Therefore, studies are needed to characterize the precise interaction of chronic airway diseases (such as asthma) and of biologics (such as Omalizumab) with SARS-CoV-2 infections in humans. We report a case of a 52-year-old man with severe allergic asthma treated with Omalizumab with no evidence of an asthma exacerbation, loss of asthma control or pneumonia during symptomatic COVID-19 disease. We hypothesize that the underlying disease (allergic asthma) or the antibody used for treatment (Omalizumab), or both, might have exerted protective effects.	./cache/cord-336026-x02f7byo.txt	./txt/cord-336026-x02f7byo.txt